Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Karyopharm (Nasdaq: KPTI) announced that its senior management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:30 a.m. ET in New York.
A live webcast will be available under the company’s Investor "Events & Presentations" page and the presentation will be available for replay following the event.
Positive
- None.
Negative
- None.
News Market Reaction – KPTI
In the Dec 1 session, KPTI gained 2.31%, reflecting a moderate positive market reaction. Argus tracked a peak move of +18.3% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Conference participation | Neutral | +2.4% | Announcement of Baird virtual fireside chat with external expert. |
| Dec 01 | Inducement grants | Neutral | -6.8% | Stock options and RSUs granted to seven new employees. |
| Dec 01 | Conference participation | Neutral | +2.3% | Piper Sandler fireside chat with webcast and replay access. |
| Nov 03 | Inducement grants | Neutral | +4.7% | RSU award to a new hire under inducement plan. |
| Nov 03 | Earnings and update | Neutral | +4.7% | Q3 2025 results, guidance reaffirmation and trial enrollment update. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has centered on conferences, inducement grants, and Q3 results, with most items followed by positive single-day price reactions despite mixed fundamental disclosures.
Over the last two months, Karyopharm’s news flow included multiple conference participations, inducement equity grants, and Q3 2025 financial results. The Piper Sandler conference appearance on Dec 4, 2025 and Baird fireside chat were both followed by modest gains. Inducement grants on Nov 3 and Nov 30, 2025 produced mixed reactions, while the Q3 earnings release highlighting $44.0M revenue and continued net loss saw shares rise. Today’s conference notice fits this cadence of largely informational updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-piper-sandler-37th-annual-healthcare-conference-302624649.html
SOURCE Karyopharm Therapeutics Inc.